Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4559-4571

  Goldstein, Rebecca L ^a,b   Yang, Shao Ning ^b   Taldone, Tony ^c   Chang, Betty ^d   Gerecitano, John ^b,c   Elenitoba Johnson, Kojo ^e   Shaknovich, Rita ^b   Tam, Wayne ^b   Leonard, John P ^b   Chiosis, Gabriela ^c   Cerchietti, Leandro ^b   Melnick, Ari ^a,b  

^a Department of Pharmacology ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PHARMACYCLICS INC   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; HEAT SHOCK PROTEIN 90; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE SYK; PU H 71; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 9H-PURINE-9-PROPANAMINE, 6-AMINO-8-((6-IODO-1,3-BENZODIOXOL-5-YL)THIO)-N-(1-METHYLETHYL)-; AGAMMAGLOBULINAEMIA TYROSINE KINASE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE; SYK PROTEIN, HUMAN;

ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER COMBINATION CHEMOTHERAPY; CELL KILLING; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; EX VIVO STUDY; FUNCTIONAL ASSESSMENT; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; XENOGRAFT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIOXOLES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROTEIN-TYROSINE KINASES; PROTEOMICS; PURINES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SYK KINASE;

EID: 84948822926     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80714     Document Type: Article

References (27)

1. Wright G, Tan B, Rosenwald A, Hurt EH, Wiest-ner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991-9996.
2. Coiffier B, et al. CHOP chemotherapy plus rit-uximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
3. Cerchietti LC, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15(12):1369-1376.
4. Caldas-Lopes E, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA. 2009;106(20):8368-8373.
5. Moulick K, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011;7(11):818-826.
6. Mollapour M, et al. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competi-tive inhibitors. Mol Cell. 2014;53(2):317-329.
7. Moorhead GB, et al. Displacement affinity chro-matography of protein phosphatase one (PP1) complexes. BMC Biochem. 2008;9:28.
8. Jensen LJ, et al. STRING 8-A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009; 37(Database issue):D412-D416.
9. Davis RE, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
10. Trentin L, et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood. 2008;112(12):4665-4674.
11. Gauld SB, Cambier JC. Src-family kinases in B-cell development and signaling. Oncogene. 2004;23(48):8001-8006.
12. Bolte S, Cordelieres FP. A guided tour into subcel-lular colocalization analysis in light microscopy. J Microsc. 2006;224(pt 3):213-232.
13. Chen L, et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826-838.
14. Gimpl G, Gehrig-Burger K. Cholesterol reporter molecules. Biosci Rep. 2007;27(6):335-358.
15. Karnell FG, Brezski RJ, King LB, Silverman MA, Monroe JG. Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J Biol Chem. 2005;280(27):25621-25628.
16. Cheng PC, Brown BK, Song W, Pierce SK. Translocation of the B cell antigen receptor into lipid rafts reveals a novel step in signaling. J Immunol. 2001;166(6):3693-3701.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
18. Gerecitano JM, et al. Using 124-I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71. J Clin Oncol. 2013;31(suppl):abstr 11076.
19. Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microar-ray. Blood. 2004;103(1):275-282.
20. Nayar U, et al. Targeting the Hsp90-associated viral oncoproteome in gamma-herpesvirus-associated malignancies. Blood. 2013;122(16):2837-2847.
21. Grammatikakis N, et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem. 2002;277(10):8312-8320.
22. Bijlmakers MJ, Marsh M. Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol Biol Cell. 2000;11(5):1585-1595.
23. Giannini A, Bijlmakers MJ. Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Mol Cell Biol. 2004;24(13):5667-5676.
24. Chen L, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230-2237
25. Wilson WH, et al. The Bruton's Tyrosine Kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Presented at: 54th Annual ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, Georgia, USA.
26. Qu Z, Wang S, Teng R, Yi X. PU-H71 effectively induces degradation of IKB kinase p in the presence of TNF-a. Mol Cell Biochem. 2014; 386(1-2):135-142.
27. Mathews Griner LA, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111(6):2349-2354.